SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-20-301981
Filing Date
2020-11-24
Accepted
2020-11-24 07:15:28
Documents
2
Period of Report
2020-11-23
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d63288d8k.htm 8-K 24193
2 EX-99.1 d63288dex991.htm EX-99.1 10332
  Complete submission text file 0001193125-20-301981.txt   35773
Mailing Address 2280 INWOOD ROAD DALLAS TX 75235
Business Address 2280 INWOOD ROAD DALLAS TX 75235 (214) 612-0000
Taysha Gene Therapies, Inc. (Filer) CIK: 0001806310 (see all company filings)

IRS No.: 843199512 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39536 | Film No.: 201339880
SIC: 2836 Biological Products, (No Diagnostic Substances)